Search

Displaying results 3131 - 3140 of 4301 in total
  1. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  2. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    Beractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of pho...

  3. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    Catechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin

  4. Drug

    Manganese cation

    go.drugbank.com/drugs/DB06757
    ApprovedInvestigationalNutraceutical

    [A263687, A263662] In humans, manganese regulates several physiological processes by acting as a cofactor for proteins [A263657, A263662, A263667] making it an essential metal for normal development and

  5. Drug

    Flavin mononucleotide

    go.drugbank.com/drugs/DB03247
    ApprovedInvestigational

    [L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on

  6. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.

  7. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition

  8. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.

  9. Drug

    Ioxaglic acid

    go.drugbank.com/drugs/DB09313
    ApprovedWithdrawn

    Ioxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opa...

  10. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria. It was approved for marketing ...